These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The expression of RUNDC3B is associated with promoter methylation in lymphoid malignancies. Burmeister DW; Smith EH; Cristel RT; McKay SD; Shi H; Arthur GL; Davis JW; Taylor KH Hematol Oncol; 2017 Mar; 35(1):25-33. PubMed ID: 26011749 [TBL] [Abstract][Full Text] [Related]
5. Aberrant epigenetic gene regulation in lymphoid malignancies. Taylor KH; Briley A; Wang Z; Cheng J; Shi H; Caldwell CW Semin Hematol; 2013 Jan; 50(1):38-47. PubMed ID: 23507482 [TBL] [Abstract][Full Text] [Related]
6. Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies. Sun RF; Yu QQ; Young KH Chronic Dis Transl Med; 2018 Mar; 4(1):29-44. PubMed ID: 29756121 [TBL] [Abstract][Full Text] [Related]
7. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
8. Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies. Wang LQ; Liang R; Chim CS Expert Rev Mol Diagn; 2012 Sep; 12(7):755-65. PubMed ID: 23153241 [TBL] [Abstract][Full Text] [Related]
9. Lymphoid malignancies: many tumor types, many altered genes, many therapeutic challenges. Dalla-Favera R J Clin Invest; 2012 Oct; 122(10):3396-7. PubMed ID: 23023709 [TBL] [Abstract][Full Text] [Related]
12. Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications. Yang X; Wong MPM; Ng RK Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527484 [TBL] [Abstract][Full Text] [Related]
13. Aberrant DNA methylations in chondrosarcoma. Liu P; Shen JK; Xu J; Trahan CA; Hornicek FJ; Duan Z Epigenomics; 2016 Nov; 8(11):1519-1525. PubMed ID: 27686001 [TBL] [Abstract][Full Text] [Related]
17. The Role of Tumor-Associated Macrophages in Hematologic Malignancies. Cencini E; Fabbri A; Sicuranza A; Gozzetti A; Bocchia M Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298810 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic target discovery and drug development in cancer stem cells for leukemia and lymphoma: from bench to the clinic. Laranjeira AB; Yang SX Expert Opin Drug Discov; 2016 Nov; 11(11):1071-1080. PubMed ID: 27626707 [TBL] [Abstract][Full Text] [Related]
19. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Kipps TJ Cancer J; 2021 Jul-Aug 01; 27(4):306-313. PubMed ID: 34398557 [TBL] [Abstract][Full Text] [Related]
20. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies. Bhatt V; Alejandro L; Michael A; Ganetsky A Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]